178 related articles for article (PubMed ID: 35859711)
1. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
[TBL] [Abstract][Full Text] [Related]
2. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia Imperils Postoperative Long-Term Survival in HCC Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Propensity Score Matching Analysis.
Kong Q; Yi M; Teng F; Li H; Chen Z
J Hepatocell Carcinoma; 2023; 10():1367-1377. PubMed ID: 37605756
[TBL] [Abstract][Full Text] [Related]
4. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study.
Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291786
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
7. Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma.
Xiong KG; Lin TS; Kong JF; Lin QB; Chen LF; Ke KY
Medicine (Baltimore); 2023 Mar; 102(9):e33062. PubMed ID: 36862923
[TBL] [Abstract][Full Text] [Related]
8. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
[TBL] [Abstract][Full Text] [Related]
9. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection.
Lin YP; Lin SH; Wang CC; Lin CC; Chen DW; Chuang CH; Huang PY; Hung CH; Yang SY; Cho WR; Chen YS; Tsai MC
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442328
[TBL] [Abstract][Full Text] [Related]
10. Sex Differences in the Impact of Metabolic Dysfunction-associated Fatty Liver Disease on the of Patients with Hepatocellular Carcinoma After Radical Resection.
Huang J; Wei S; Tang Y; Zhang Q; Luo H; Tang Z; Tang Y; Liu H; Huang W; Dong X; Yang J
J Cancer; 2023; 14(7):1107-1116. PubMed ID: 37215444
[No Abstract] [Full Text] [Related]
11. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
Xiong KG; Ke KY; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
World J Surg Oncol; 2024 May; 22(1):117. PubMed ID: 38698475
[TBL] [Abstract][Full Text] [Related]
12. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection.
Xiong KG; Ke KY; Chen LF; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
Hepatobiliary Pancreat Dis Int; 2023 Aug; 22(4):366-372. PubMed ID: 35466065
[TBL] [Abstract][Full Text] [Related]
13. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B-A Retrospective Cohort Study.
Wang QX; Xue J; Shi MJ; Xie YB; Xiao HM; Li S; Lin M; Chi XL
Diabetes Metab Syndr Obes; 2022; 15():2311-2322. PubMed ID: 35942038
[TBL] [Abstract][Full Text] [Related]
14. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.
Yang DL; Liu SP; Wang HL; Li JR; Su JY; Li MJ; Teng YX; Deng ZJ; Li ZH; Huang JL; Guo PP; Ma L; Li ZZ; Zhong JH
Infect Agent Cancer; 2024 May; 19(1):21. PubMed ID: 38693556
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.
Liu L; Xie S; Teng YX; Deng ZJ; Chen K; Liu HT; Huo RR; Liang XM; Guo PP; Yang DL; Ma L; Xiang BD; Li LQ; Zhong JH
Front Oncol; 2021; 11():783339. PubMed ID: 35127490
[TBL] [Abstract][Full Text] [Related]
17. Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease.
Tan YW; Wang JM; Zhou XB
World J Hepatol; 2023 Feb; 15(2):237-254. PubMed ID: 36926239
[TBL] [Abstract][Full Text] [Related]
18. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
19. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]